Enveric Biosciences
ENVB
9 hedge funds and large institutions have $3.42M invested in Enveric Biosciences in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
2,274% more capital invested
Capital invested by funds: $144K → $3.42M (+$3.27M)
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
200% more funds holding
Funds holding: 3 → 9 (+6)
5.55% more ownership
Funds ownership: 0.17% → 5.73% (+5.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$664K |
| 3 |
VF
Virtu Financial
New York
|
+$664K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$245K |
| 5 |
EGM
Engineers Gate Manager
New York
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$43K |
ENVB Hedge Fund Activity: Q1 2021 in Review
9 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q1 2021, worth a combined $3.42M — up 2,274% from $144K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ENVB positions and 1 closed out — a net gain of 6 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $2.2M. The largest seller was Citadel Advisors, exiting entirely with an estimated $43K sold.
- 9 institutional investors held Enveric Biosciences (ENVB) as of Q1 2021, up from 3 in Q4 2020.
- Funds reported $3.42M of Enveric Biosciences stock for Q1 2021, up 2,274% quarter-over-quarter.
- 7 funds opened new Enveric Biosciences positions in Q1 2021 and 1 closed out, a net change of +6 holders.
- The largest Enveric Biosciences buyer in Q1 2021 was BlackRock, an estimated $2.2M added.
- The largest Enveric Biosciences seller in Q1 2021 was Citadel Advisors, an estimated $43K sold.
Based on aggregated 13F filings for Q1 2021.